v3.25.4
Other (Income)/Deductions—Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 19, 2023
Mar. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Derivative [Line Items]          
Interest costs capitalized     $ 166 $ 182 $ 160
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date     32 114 165
Realized gain     (35) 1,122 1,754
Intangible asset impairments     4,940   3,000
Charge related to expected sale of facilities       420  
Pre-tax gain on divestiture $ 222       222
Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments       2,900 2,900
Biopharma [Member] | Other Developed Technology Rights, In-Process Research and Development and Finite-Lived Licensing Agreement [Member]          
Derivative [Line Items]          
Intangible asset impairments       436  
Biopharma [Member] | Other In Process Research and Development and Developed Technology Rights [Member]          
Derivative [Line Items]          
Intangible asset impairments         486
U.S. Sterile Injectable and Hospital Products [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments     1,000    
IPR&D [Member]          
Derivative [Line Items]          
Intangible asset impairments [1]     3,903    
IPR&D [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments     3,900    
IPR&D [Member] | disitamab vedotin [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments     1,600 200  
IPR&D [Member] | Tukysa [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments     820 400  
IPR&D [Member] | osivelotor [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments     820    
IPR&D [Member] | B7H4V (felmetatug vedotin) [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments       1,000  
IPR&D [Member] | Etrasimod (Velsipity) [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments         1,400
Haleon [Member]          
Derivative [Line Items]          
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date       (1,000)  
Gain on sale of equity method investment   $ 144 945 945  
Telavant Holdings, Inc. [Member]          
Derivative [Line Items]          
Realized gain         1,700
Cerevel Therapeutics Holdings, Inc. [Member]          
Derivative [Line Items]          
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date         (297)
BioNTech [Member]          
Derivative [Line Items]          
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date         292
ViiV [Member]          
Derivative [Line Items]          
Dividend income     265 272 265
ViiV [Member] | Biopharma [Member]          
Derivative [Line Items]          
Dividend income     265 272 265
Nimbus [Member]          
Derivative [Line Items]          
Dividend income         211
Developed Technology Rights [Member]          
Derivative [Line Items]          
Intangible asset impairments [1]     560    
Developed Technology Rights [Member] | Zavzpret [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments       435  
Developed Technology Rights [Member] | Prevnar 13 [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments         $ 964
Brand [Member]          
Derivative [Line Items]          
Intangible asset impairments [1]     $ 240    
Brand [Member] | Medrol [Member] | Biopharma [Member]          
Derivative [Line Items]          
Intangible asset impairments       $ 475  
[1] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.